Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the worldâs largest biotechnology company and the global leader in in-vitro diagnostics.
Webinar: Prognostic Tools in Breast Cancer Care
In collaboration with iBreastBook, Johan Hartman, co-founder of Stratipath, participated in a webinar focused on predictive and prognostic tools in breast cancer care. Johan delivered an insightful lecture on: âAI-Based Image Analysis: A Cost-Effective Alternative to Genomic Profilingâ. We were honored to have an excellent lineup of speakers and panelists who shared their expertise:– Abeer […]
Stratipath Joins Forces with Colombian Pathology Leaders to Advance Digital Pathology
Stratipath is thrilled to announce our active role in advancing Digital Pathology in Colombia, driven by the collaborative efforts between the Swedish Association of Pathology and the Colombian Association of Pathology. Our Co-founder and CMO, Professor Johan Hartman, has been at the forefront of these discussions, bringing invaluable insights from Sweden’s experience with Digital Pathology. […]
A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breastâthe first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.
Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman
Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman
Stratipath was honored with the Dream Award at the Techarenan Challenge in Almedalen.
Stratipath was honored with the Dream Award at the Techarenan Challenge in Almedalen.
Seminar – Almedalen. âAI can predict relapse in breast cancer – How does this affect breast cancer care?â
Seminar – Almedalen. âAI can predict relapse in breast cancer – How does this affect breast cancer care?â
Seminar – Almedalen âNo precision medicine without pathologyâ
Seminar – Almedalen âNo precision medicine without pathologyâ
Stratipath Breast AI-based risk profiling for breast cancer is now available for clinical use in the UK.
Stratipath Breast, is now officially registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration allows healthcare providers across the United Kingdom access to the AI-based prognostic tool for breast cancer risk profiling.
Stratipath co-founder Professor Johan Hartman, is discussing the future of precision diagnostics in Medtech Magazine
Stratipath co-founder Professor Johan Hartman, is discussing the future of precision diagnostics in Medtech Magazine